Investor Webinar – 15 October 2026
Solvonis Therapeutics plc announced an investor webinar scheduled for October 15, 2026, to discuss its strategy in addiction and mental health therapeutics, focusing on its late clinical-stage small-molecule treatments. The company will provide updates on its alcohol use disorder franchise, including the UK Phase 3 program for SVN-001 and planned European expansion, as well as SVN-002's development for the US market. Additionally, Solvonis will cover its proprietary drug development pipeline, featuring SVN-015 for stimulant use disorder and SVN-114 for post-traumatic stress disorder, highlighting key clinical, regulatory, and commercial milestones.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
LONDON – 06 October 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, Solvonis Therapeutics plc (“Solvonis” or the “Company”), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders, is pleased to announce an investor webinar featuring Anthony Tennyson, Chief Executive Officer, and Professor David Nutt, Chief Scientific Officer, to be broadcast at 6:00pm BST on Thursday, 15 October 2026.
The webinar comes amid growing interest in new approaches to mental health treatment, highlighted by recent BBC coverage exploring whether psychedelic therapies could become part of mainstream NHS care:
Could psychedelic therapy become NHS treatment for mental health?
Against this backdrop, Solvonis will discuss its strategy for translating advances in neuropsychopharmacology into potential treatments for addiction and psychiatric disorders. The Company combines the repurposing of established medicines for nearer-term clinical value with proprietary drug discovery for longer-term growth.
The webinar will cover:
Building an international alcohol use disorder franchise: SVN-001’s ongoing UK Phase 3 programme, recently announced Phase 2 analyses and planned European expansion, alongside SVN-002’s development for the US market.
Developing proprietary medicines: SVN-015 for stimulant use disorder, supported by NIDA-funded evaluation, and SVN-114 for post-traumatic stress disorder.
Delivering the strategy: the clinical, regulatory and commercial milestones underpinning Solvonis’ ambition to become a leader in addiction and mental health therapeutics.
Hosted by Turner Pope Investments and chaired by analyst Barry Gibb, the recorded webinar is open to shareholders and other interested investors. It will include a Q&A addressing questions submitted in advance through the registration process.
To register and submit questions, please visit:
| solvonis.com | X |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.